A review of secukinumab in psoriasis treatment
| Autor: | Steven R. Feldman, Scott H Berg, Rima I. Ghamrawi, Esther A. Balogh |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
medicine.medical_specialty
Immunology Disease Antibodies Monoclonal Humanized 030207 dermatology & venereal diseases 03 medical and health sciences Psoriatic arthritis 0302 clinical medicine Quality of life Psoriasis Area and Severity Index Psoriasis IL-17A Humans Immunology and Allergy Medicine biologics psoriatic arthritis 030203 arthritis & rheumatology business.industry secukinumab Arthritis Psoriatic Interleukin-17 psoriasis medicine.disease Dermatology Clinical trial Treatment Outcome Oncology Quality of Life Cytokines Secukinumab business Psoriasis treatment |
| Zdroj: | Berg, S H, Balogh, E A, Ghamrawi, R I & Feldman, S R 2021, ' A review of secukinumab in psoriasis treatment ', Immunotherapy, vol. 13, no. 3, pp. 201-216 . https://doi.org/10.2217/imt-2020-0195 |
| ISSN: | 1750-7448 1750-743X |
| DOI: | 10.2217/imt-2020-0195 |
| Popis: | Psoriasis is a systemic immunologic disorder associated with decreased quality of life and numerous co-morbidities, including psoriatic arthritis and cardiovascular disease. Secukinumab, a fully human IgG1 monoclonal antibody, selectively binds IL-17A and is approved by the US FDA and European Medicines Agency for moderate-to-severe plaque psoriasis and psoriatic arthritis. This review examines the efficacy and safety of secukinumab for the treatment of psoriasis using the literature retrieved from the PubMed database. In clinical trials, treatment with secukinumab led to rapid and sustained improvement in Psoriasis Area and Severity Index (PASI) scores, with PASI 90 response rates up to 68.5% at 5 years. Long-term clinical trial and real-world data have established secukinumab as a safe and effective treatment for psoriasis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|